Westar Capital Retained as Corporate Advisors Following...

Westar Capital Retained as Corporate Advisors Following Successful Capital Raise MELBOURNE, Australia, 12 April 2018: Dimerix Limited or the “Company” (ASX: DXB), a clinical stage biotechnology company, today announced the retention of Westar Capital Limited (”Westar”) as corporate advisors to the Company. Today’s agreement is the continuation of a prior period under which Westar had been mandated to provide corporate advisory services. Westar has acted as corporate advisor for the last 2 years and was the lead manager for the 2016 capital raise and again during the Company’s recent oversubscribed capital raise through which at total of AU$7.5m in new funding was secured to support the development of Dimerix’s DMX-200 program in kidney disease and pipeline. Under the agreement, and as part of Westar’s performance-driven remuneration, Dimerix has agreed to issue 500,000 unlisted options exercisable at 25 cents per share, expiring two years from the date of issue and 1,500,000 unlisted options exercisable at 50 cents per share and expiring two years from the date of issue. The issue date is at Westar’s discretion, but cannot occur beyond the date on which the first patient is recruited for Dimerix’s coming phase 2 human clinical trials of DMX-200. The issue will be made pursuant to the Company’s placement capacity under ASX listing Rule 7.1.